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Predictors of clinical remission in cats with diabetes mellitus
Abstract
BACKGROUND: Clinical remission is frequent in cats with well-controlled diabetes mellitus, but few
studies explored predictors of this phenomenon.
HYPOTHESIS: Data retrieved from medical records at admission might be valuable to identify
likelihood of remission and its duration in diabetic cats.
ANIMALS: Ninety cats with newly diagnosed diabetes, followed-up until death or remission.
METHODS: Retrospective cohort study. Data were collected from records at admission, including
history, signalment, physical examination, haematology, and biochemical profile, and the occurrence
and duration of remission, defined as normoglycemia without insulin for ≥4 weeks. Predictors of
remission were studied with univariate and multivariate logistic regression. Factors associated with
remission duration were analyzed with Kaplan-Meier and Cox proportional hazard models.
RESULTS: Forty-five (50%) cats achieved remission, after a median time of 48 days (range: 8-216). By
study end, median remission duration was 114 days (range: 30-3,370) in cats that died and 151 days
(range: 28-1,180) in alive cats. Remission was more likely with higher age (OR: 1.23, 95% CI:
1.04-1.46; P=.01) and less likely with increased serum cholesterol (OR: 0.36, 95% CI: 0.11-0.87;
P=.04). Remission was longer with higher body weight (HR: 0.65, 95% CI: 0.42-0.99; P=.04) and
shorter with higher blood glucose (HR: 1.01, 95% CI: 1.00-1.02; P=.02).
CONCLUSIONS AND CLINICAL IMPORTANCE: Age, body weight, cholesterol, and glucose levels
are suggested for prediction of remission or its duration in diabetic cats. Older cats developing diabetes
may have a better outcome, possibly suggesting a slower disease progression.
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Abstract 24 
Background―Clinical remission is frequent in cats with well-controlled diabetes 25 
mellitus but few studies explored predictors of this phenomenon. Corticosteroid 26 
administration before diagnosis, absence of polyneuropathy, strict glycemic control and 27 
use of insulin glargine were associated with remission, whereas initial blood glucose, 28 
fructosamine, insulin, insulin growth factor-1 and glucagon levels were not. 29 
Hypothesis―Data retrieved from medical records at admission may predict remission 30 
and its duration in diabetic cats. 31 
Animals―90 cats with newly diagnosed diabetes, followed-up until death or remission. 32 
Methods―Collected data included history, signalment, physical examination, 33 
haematology and biochemical profile, and the occurrence and duration of remission, 34 
defined as normoglycemia without insulin for ≥4 weeks. Predictors of remission were 35 
studied with univariate and multivariate logistic regression. Factors associated with 36 
remission duration were analyzed with Kaplan-Meier and Cox proportional hazard 37 
models. 38 
Results―45 (50.0%) cats achieved remission, after a median time of 48 days (range: 8-39 
216). By study end, median remission duration was 114 days (range: 30-3370) in cats 40 
that died and 151 days (range: 28-1180) in alive cats. Remission was more likely with 41 
increasing age (OR: 1.23, CI95%:1.04-1.46; p=0.01) and less with increased serum 42 
cholesterol (OR: 0.36, CI95%:0.11-0.87; p=0.04). Remission was longer with 43 
increasing body weight (HR: 0.65, CI95%:0.42-0.99; p=0.04) and shorter with 44 
increasing blood glucose (HR: 1.01, CI95%:1.00-1.02; p=0.02). 45 
Conclusions and clinical Importance―Age, body weight, cholesterol and glucose 46 
levels at admission may be valuable to anticipate remission or its duration in diabetic 47 
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cats. Older cats developing diabetes may have a better outcome, possibly suggesting a 48 
slower disease progression. 49 
 50 
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Diabetes mellitus is one of the most commonly encountered endocrine diseases in cats.1 52 
Insulin therapy is the most effective means to achieve glycemic control and to avoid 53 
life-threatening complications in diabetic cats.2 Interestingly, 41% to 84% of affected 54 
cats have been reported to maintain normoglycemia without exogenous insulin within 55 
weeks to months of beginning therapy. 3-7 The term diabetic remission or transient 56 
diabetes is used in cats when insulin administration can be withdrawn for at least 4 57 
consecutive weeks and when, beside restoration of normal glucose concentrations, 58 
clinical signs of diabetes have disappeared.5 Viability of β-cells may not have fully 59 
recovered, as shown by a reduced number of pancreatic islet cells in diabetic cats 60 
examined during remission.3 The reason why remission occurs in some cats is 61 
uncertain. Because feline β-cells are very susceptible to the detrimental effects of excess 62 
glucose,8 it is hypothesized that an adequate control of glycemia with insulin may 63 
reverse glucose toxicity in the endocrine pancreas.3-7 64 
A small number of investigations addressed diabetic remission in cats to identify 65 
predictors of this phenomenon at the time of admission. At our institution it was shown 66 
that serum concentrations of glucose, fructosamine, insulin, glucagon and insulin 67 
growth factor-1 are not different between diabetic cats that achieved remission and 68 
those that did not.4 Nelson and co-workers, by inducing β-cell secretion with a glucagon 69 
stimulation test, found similar insulin area under the curve in diabetic cats that required 70 
or not long lasting insulin treatment.3 During remission glucagon-induced insulin 71 
secretion was comparable to healthy cats.3 Recently, another group performed a study 72 
based on a questionnaire to diabetic cat owners participating in an internet forum and 73 
showed that strict glycemic control, administration of corticosteroids previous to 74 
diagnosis, and absence of polyneuropathy were more likely in cats with remission;6 age, 75 
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gender, body weight, renal failure and hyperthyroidism were not useful predictors.6 In 76 
addition, they demonstrated that the use of insulin glargine increased the chance of 77 
remission in diabetic cats.7 In a study we observed that diabetic cats with ketoacidosis 78 
can also attain normoglycemia and discontinue insulin.5 Based on an arginine 79 
stimulation test, we recently found that cats with diabetes achieving remission have 80 
higher area under the curve of the glucagon-to-insulin ratio than cats with life-long 81 
insulin requirement, suggesting a possible role for glucagon in the pathogenesis of 82 
diabetic remission.a 83 
Improving anticipation of remission would be very helpful to increase motivation of 84 
owners to treat their diabetic cats. Achieving remission is advantageous because cats 85 
benefit from better quality of life and costs of treatment are decreased. Therefore, the 86 
aim of the present study was to explore factors that at the time of admission may predict 87 
remission in diabetic cats; we used data retrieved from history, signalment, physical 88 
examination, and haematology and biochemical profile. In addition, the same factors 89 
were studied to identify possible associations with duration of remission. 90 
91 
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Materials and Methods 91 
Cats 92 
Medical records of all diabetic cats admitted to the Clinic for Small Animal Internal 93 
Medicine, Vetsuisse Faculty, University of Zurich (Switzerland), between January 2000 94 
and July 2009 were reviewed. Cats were included in the study if they had newly 95 
diagnosed diabetes and were followed-up at least until remission was achieved or, 96 
otherwise, until death. Cats with ketoacidosis or concurrent diseases were also included. 97 
From all records, information was retrieved on admission pertaining history (including 98 
previous administration of corticosteroids and progestagens), signalment, physical 99 
examination and blood work. Ketoacidosis or any concurrent disease diagnosed on 100 
admission was recorded. The type of insulin administered after discharge was also 101 
retrieved. 102 
Whether the diabetic cat had achieved clinical remission, that is, insulin was not 103 
required to maintain normoglycemia, and how long remission had lasted was obtained 104 
from follow-up records. Similar to previous studies performed by our group, only cats 105 
that did not need insulin for at least 4 consecutive weeks were considered in 106 
remission.5,a As a standard procedure at our institution, all diabetic cats had been 107 
reassessed at 1, 2-3, 4-6, 8-12 weeks and 6 months following discharge, and thereafter 108 
every 3-6 months, regardless of remission. Additional evaluations had been planned 109 
according to individual needs. 110 
 111 
Statistical analysis 112 
To identify predictors of remission, univariate binary logistic regression analysis was 113 
performed with all diabetic cats and the following factors used as dichotomous 114 
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variables: previous administration of corticosteroids and progestagens, gender (male or 115 
female), breed (pure- or cross-bred), increase of leukocyte count, serum cholesterol, 116 
total protein, creatinine, urea, potassium, bilirubin and lipase, decrease of hematocrit, 117 
serum albumin and potassium, and presence of ketoacidosis or of concurrent disease. 118 
The type of insulin administered, either porcine insulin zinc suspensionb or insulin 119 
glarginec, was also included in the analysis; cats that received one of the two insulin 120 
types but died before discharge were not considered. Blood parameters such as glucose 121 
and fructosamine that are typically increased in untreated diabetic cats were investigated 122 
as continuous variables. Age and body weight were also studied as continuous 123 
variables. Factors that at univariate analysis yielded p<0.25 were further used to assess 124 
their confounding effect with multivariate binary logistic regression. Factors whose 125 
results were not available in more than 20% of cats were excluded from the multivariate 126 
analysis. 127 
In the group of cats that had insulin discontinued, analysis was conducted to identify 128 
factors associated with duration of remission. The influence of above dichotomous 129 
variables was studied with Kaplan-Meier product-limit followed by log rank test; only 130 
dichotomous variables represented by at least 10 cases in either category were 131 
considered. The influence of continuous variables was studied with univariate Cox 132 
proportional hazard model. Factors with p<0.25 were further used to assess their 133 
confounding effect employing the Cox proportional hazard model. Cats in remission 134 
were censored if they were still alive by the study end. 135 
Significance was considered for p<0.05. Statistical analysis was conducted with 136 
softwares.d,e 137 
138 
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Results 138 
Cats 139 
Of 275 diabetic cats admitted during the study period, 90 met the inclusion criteria and 140 
were included in the analysis. Forty-five (50.0%) of the 90 diabetic cats achieved 141 
remission and 45 (50.0%) did not. 142 
 143 
Cats with diabetic remission 144 
In the group that achieved remission, median age at diagnosis was 12 years (range: 2-145 
17). Thirty-two (71.1%) cats were neutered male and 13 (28.9%) spayed female. Thirty 146 
(66.7%) cats were cross-bred (i.e., domestic short- or longhair), and 11 (33.3%) were 147 
pure-bred, including 3 Persian, 2 each Maine Coon and Siamese, and one each 148 
Abyssinian, Birman, Burmese and Ragdoll; breed was not recorded in 4 cats. Median 149 
body weight was 5.2 kg (range: 2.5-8.4). Corticosteroids or progestagens had been 150 
administered to 5 cats, up to 3 months prior to admission. 151 
On admission median serum glucose was 419 mg/dL (range: 248-1251; reference range: 152 
90-180), fructosamine was 588 µmol/L (range: 371-984; reference range: 200-300). 153 
Ketoacidosis was diagnosed in 13 (28.9%) cats, concurrent diseases were documented 154 
in 20 (44.4%) cats, including 3 each with lung disease or suspected pancreatitis, 2 each 155 
with cystitis, feline immunodeficiency virus or skin disease, and one each with bone 156 
fracture, cholangiohepatitis, enteritis, hyperthyroidism, lymphoma, pure red cell aplasia, 157 
renal failure or stomatitis. The frequency of abnormal blood results is summarized in 158 
Table 1. 159 
After discharge, 21 (46.7%) cats were treated with insulin glargine and 23 (53.3%) with 160 
porcine insulin zinc suspension; in one cat the type of insulin is unknown. Additional 161 
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therapy was administered to treat concurrent diseases (data not shown). Median time 162 
from discharge to remission was 48 days (range: 8-216); 25% of cats achieved 163 
remission within 27 days, 75% within 102 days, and only one cat after 6 months (Fig. 164 
1). By the end of the study, median remission duration was 114 days (range: 30-3370) 165 
in cats that were followed-up until death (n=15) and 151 days (range: 28-1180) in cats 166 
that were still alive (n=30). Six of the 45 (13.3%) cats with remission did not require 167 
insulin for more than 1000 days; one of them for more than 9 years. Overall, insulin 168 
therapy needed to be resumed to control hyperglycemia in 13 (28.9%) cats, including 6 169 
of the cats that died and 7 of those that were still alive at the study end. None of these 170 
13 cats experienced a further period of clinical remission. 171 
 172 
Cats without diabetic remission 173 
In the group that did not achieve diabetic remission, median age at diagnosis was 11 174 
years (range: 2-18); in one cat age was unknown. The cats consisted of 30 (66.7%) 175 
neutered male and 15 (33.3%) spayed female. Twenty-nine (70.7%) cats were domestic 176 
short- or longhair, and 12 (29.3%) were pure-bred, including 2 each Maine Coon and 177 
Siamese, and one each Persian, Havana Brown, Birman, Burmese, Chartreux, 178 
Norwegian Forest, Oriental shorthair and Russian Blue; breed was not recorded in 4 179 
cats. Median body weight was 4.8 kg (range: 3.0-9.8); body weight was not available in 180 
one cat. Corticosteroids or progestagens were administered to 5 cats and up to 4 months 181 
prior to admission. 182 
On admission median serum glucose was 436 mg/dL (range: 243-990) and fructosamine 183 
was 613 µmol/L (range: 435-968). Ketoacidosis was diagnosed in 17 (37.8%) cats and 184 
concurrent diseases were documented in 24 (53.3%) cats, including 3 each with 185 
 10 
cholangiohepatitis, hypertrophic cardiomyopathy or lung disease, 2 each with cystitis, 186 
renal failure or stomatitis, and one each with acromegaly, enteritis, epilepsy, 187 
histiocytosis, idiopathic hypercalcemia, lymphoma, megacolon, skin disease or 188 
suspected pancreatitis. The frequency of abnormal blood results is summarized in Table 189 
1. 190 
After discharge, 8 (30.8%) cats were treated with insulin glargine and 18 (69.2%) with 191 
porcine insulin zinc suspension. Twelve cats received regular insulin on admission 192 
because of ketoacidosis and did not survive to discharge. Seven additional cats died 193 
before discharge; 3 of them received insulin glargine, lente insulin or regular insulin, 194 
and 4 died previous to insulin therapy. Additional therapy was administered to treat 195 
concurrent diseases. 196 
 197 
Predictors of diabetic remission 198 
Factors retrieved from medical records on admission were studied to assess their role as 199 
predictors of diabetic remission. Using univariate logistic regression analysis, increasing 200 
age and the use of insulin glargine were more likely in diabetic cats that achieved 201 
remission, whereas low hematocrit and increased cholesterol, urea and bilirubin were 202 
more likely in diabetic cats that did not achieve remission (Table 1). Gender, breed, 203 
body weight, administration of corticosteroids or progestagens, leukocyte count, serum 204 
glucose, fructosamine, total protein, albumin, creatinine, potassium, lipase, ketoacidosis 205 
and concurrent diseases did not predict remission in our population of cats. 206 
The multivariate logistic regression model was constructed with the continuous variable 207 
age and the dichotomous variables hematocrit, cholesterol, urea and bilirubin. Type of 208 
insulin was not included because more than 20% of cats did not survive to discharge. 209 
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Based on multivariate analysis, age and serum cholesterol were independent predictors 210 
of diabetic remission (p<0.05) (Table 2). In particular, increased cholesterol decreased 211 
the chance of remission by almost 65%, and per year of age chance of remission 212 
increased by approximately 25%. Percentage of remission and age is shown in Fig. 2. 213 
Approximately 70% of cats that were older than 12 years at diagnosis achieved diabetic 214 
remission, less than 50% of cats that were between 10-12 years, and only 30-40% of 215 
cats below 9 years. The Hosmer-Lomeshow test was not significant (p=0.34) suggesting 216 
fit of the multivariate model. 217 
 218 
Factors associated with duration of diabetic remission 219 
Factors retrieved from medical records on admission were investigated to assess 220 
possible associations with the duration of diabetic remission. Results of Kaplan-Meier 221 
analysis for dichotomous variables and of univariate Cox proportional hazard model 222 
analysis for continuous variables are reported in Table 3; increasing body weight was 223 
associated with longer remission, whereas decreased hematocrit, increasing serum 224 
glucose and increased serum lipase were associated with shorter remission. Age, gender, 225 
breed, leukocyte count, serum fructosamine, cholesterol, total protein, urea and 226 
bilirubin, ketoacidosis, concurrent diseases and type of insulin were not linked to the 227 
duration of remission. The effect of administration of corticosteroids or progestagens 228 
and serum albumin, creatinine and potassium were not assessed because we observed 229 
less than 10 cases per category. 230 
Results of the multivariate Cox proportional hazard model constructed with the 231 
dichotomous variables hematocrit and serum lipase, and the continuous variables body 232 
weight and serum glucose are reported in Table 4. With the adopted model body weight 233 
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and serum glucose remained independently associated with the duration of diabetic 234 
remission (p<0.05). In particular, for a one kg increase of body weight duration of 235 
remission increased by approximately 35%, and for a one mg/dL increase of glucose in 236 
the hyperglycemic range, duration of remission decreased by approximately 1%. 237 
Duration of remission and body weight or blood glucose concentrations are shown in 238 
Fig. 3-4. The likelihood ratio test of the model yielded an overall chi-square difference 239 
significant at p<0.001, indicating that the variables accurately contributed to explaining 240 
the duration of remission. 241 
242 
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Discussion 242 
In the present study 45 of 90 (50.0%) diabetic cats achieved clinical remission, and the 243 
large majority of them within 6 months from diagnosis, similar to previous reports.3-7 244 
Despite remission being frequent in cats, few studies investigated the factors that may 245 
predict this favourable outcome already at the time of first presentation to the clinic.3-7 246 
Here, by using simple parameters retrieved on admission from history, signalment, 247 
physical examination, haematology and biochemical profile, we identified predictors of 248 
remission and of its duration. In particular, remission was more likely with increasing 249 
age, and less likely with elevated serum cholesterol. Remission was longer with 250 
increasing body weight, and shorter with increasing serum glucose. 251 
Increasing age at admission was associated with an augmented chance of diabetic 252 
remission. Specifically, for each additional year of age at first diagnosis, remission was 253 
25% more likely. This finding may be unexpected based on the notion that aging is 254 
associated with decreased β-cell function in different mammalian species.9,10 However, 255 
a study demonstrated that type 2 diabetic humans first diagnosed after 65 years of age 256 
present with a less severe disease course and less severe metabolic deterioration. At 257 
baseline and during follow-up, type 2 diabetics that were older than 65 years at 258 
diagnosis had lower fasting blood glucose and glycated hemoglobin concentrations.11 259 
The reason why diabetes in older humans evolves more slowly has not been clarified. 260 
Also in type 1 diabetic patients, younger age at diagnosis was associated with a faster 261 
progression to insulin dependency.12,13 262 
Higher than normal cholesterol reduced the chance of remission by almost 65% in 263 
diabetic cats. Most studies in humans linking hyperlipidemia to type 2 diabetes had 264 
focused on the role of triglycerides and free fatty acids but recent in vivo studies with 265 
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rodents have shown that increased cholesterol concentrations may also impair β-cell 266 
function or viability.14,15 In particular, apoE-deficient mice, which is a transgenic model 267 
with increased serum cholesterol but normal free fatty acid concentrations, had impaired 268 
glucose-stimulated insulin secretion.14 Further, isolated pancreatic islets had increased 269 
content of cholesterol, and its depletion was followed by restoration of insulin 270 
secretion.14 In another transgenic mice model characterized by hypercholesterolemia, 271 
besides impaired insulin secretion, the number and size of pancreatic islets were 272 
reduced by more than 50%.15 Therefore, increased serum cholesterol may exert a direct 273 
toxic effect on β-cells. It is possible that hypercholesterolemia also plays a primary role 274 
in the progression of diabetes in cats, eventually preventing the recovery of β-cell 275 
function or viability. Because in the present study the concentrations of serum 276 
triglycerides and of free fatty acids were not available, it cannot be excluded that these 277 
lipid metabolites had a confounding effect on the chance of remission in our cat 278 
population. However, sustained hypertriglyceridemia and increased free fatty acid 279 
concentrations did not impair insulin secretion in a recent study with healthy cats.8 280 
Based on univariate analysis, diabetic cats treated with insulin glargine tended to have 281 
an increased chance of remission. Because many cats did not survive to discharge, 282 
hence not receiving insulin glargine or porcine insulin zinc suspension, the multivariate 283 
model was not performed to assess whether the former independently predicts 284 
remission. A higher probability of diabetic remission was previously reported in cats 285 
treated with insulin glargine compared to porcine lente insulin.7 286 
The duration of diabetic remission varied widely, with some cats not requiring treatment 287 
for few months and others for many years. More than 10% of cats remained in 288 
remission for more than 1000 days and one cat for longer than 9 years. Remission 289 
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lasting more than 1000 days seems to be uncommon in cats.3,6 Insulin therapy was 290 
resumed in 13 of the 45 (28.9%) cats that had experienced remission. Likewise, in one 291 
report 37.5% of diabetic cats in remission had insulin started again to maintain 292 
normoglycemia.6 293 
To our surprise, increasing body weight was associated with longer-lasting diabetic 294 
remission; for a one kg increase of body weight at admission remission length increased 295 
by almost 35%. Obese cats are predisposed to insulin resistance, which in turns poses an 296 
excessive demand to β-cells leading to their exhaustion.16 In this setting, we assumed 297 
that the chance of remission should be reduced. Unfortunately, it was not possible to 298 
determine whether our cats with higher body weight had been obese or just were larger 299 
cats; body score was not reported in most medical records. However, body weight was 300 
not significantly decreased at the time of remission compared to body weight at first 301 
diagnosis (data not shown). Thus, it seems unlikely that remission occurred due to a 302 
reduction of body weight, which by itself should improve insulin sensitivity and, in 303 
turn, β-cell function or viability. 304 
Diabetic cats in remission presenting with higher initial blood glucose concentrations 305 
had insulin withdrawn for a shorter time. Because feline pancreatic islets are extremely 306 
susceptible to the toxic effects of excess glucose,8 it may be assumed that cats with 307 
higher glucose concentrations at initial diagnosis had more severe β-cell damage. The 308 
remaining pool of functional β-cells may thus have been more limited in these cats, 309 
hence reducing the chance of lasting remission. Typically, measurement of serum 310 
fructosamine is indicated to better assess average blood glucose during the weeks before 311 
admission.17 Different from blood glucose, however, fructosamine was not associated 312 
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with longer remission. Thus, further studies are necessary to confirm the role of blood 313 
glucose concentrations on admission. 314 
There are some limitations of our study that need to be mentioned. The retrospective 315 
nature of the investigation occasionally resulted in incomplete clinical data records. 316 
However, prospective longitudinal studies spanning over several years are difficult in 317 
veterinary medicine. Hence, including a relatively large number of cases is easier to 318 
perform in retrospective analysis. 319 
The role of feeding a specific diet, which is important to improve the control of 320 
glycemia in diabetic cats,2 was not assessed in the present series because cats were fed 321 
various types or were switched to another in many cases. Thus, the potential 322 
confounding effect of a particular diet or formulation cannot be ruled-out. 323 
Remission applies to cats that achieve normoglycemia and disappearance of clinical 324 
signs of diabetes, without insulin. According to recent studies performed at our 325 
institution,5,a we considered a cat to be in remission after initial treatment if insulin was 326 
not required for at least 4 weeks. Based on the latest American Diabetes Association 327 
statement, remission in humans with either type 1 or 2 diabetes is defined as attaining 328 
normoglycemia in the absence of active pharmacologic therapy for more than one 329 
year.18 Because of the shorter lifespan of cats, this cut-off does not seem suitable for the 330 
feline species. 331 
In summary, the present study shows that the chance of diabetic remission in cats, based 332 
on factors retrieved on admission, is higher with increasing age and lower when serum 333 
cholesterol is augmented. In addition, in cats that did not require insulin to maintain 334 
normoglycemia, duration of remission was longer with increasing body weight and 335 
shorter with increasing serum glucose. The use of these simple parameters may be 336 
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helpful to improve characterization of diabetes in cats. Additional investigation is 337 
warranted to clarify how the pathogenesis of diabetes in cats with remission differs from 338 
cats requiring long-standing insulin treatment. Disease progression may be slower in 339 
older cats and more rapid if serum cholesterol is augmented. 340 
 341 
Footnotes 342 
a Tschuor F, Furrer D, Kaufmann K, et al. Intravenous arginine stimulation test in cats 343 
with transient and non-transient diabetes mellitus. J Vet Intern Med 2006;20:725-726 344 
(abstract). 345 
b Caninsulin, Intervet International BV, Boxmeer, the Netherlands. 346 
c Lantus, Sanofi Aventis (Suisse) SA, Meyrin, Switzerland. 347 
d GraphPad Prism version 4.0, GraphPad Software, San Diego, CA. 348 
e SPSS version 11.0, SPSS Inc., Chicago, IL. 349 
350 
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Tables 398 
 399 
Table 1. Characteristics of diabetic cats with and without clinical remission, and 400 
univariate analysis of predictors of diabetic remission. 401 
Variable* 
Cats with 
remission 
Cats without 
remission 
OR CI95% p-value 
Age   1.13 0.99-1.28 0.07 
Gender 
    Neutered male 
    Spayed female 
 
32 (71.1%) 
13 (28.9%) 
 
30 (66.7%) 
15 (33.3%) 
 
1.23 
 
0.50-3.01 
 
0.65 
Breed 
    Pure-bred 
    Cross-bred 
 
11 (33.3%) 
30 (66.7%) 
 
12 (29.3%) 
29 (70.7%) 
 
0.89 
 
0.34-2.33 
 
0.81 
Body weight   0.99 0.75-1.30 0.92 
Previous administration of 
corticosteroids or progestagens 
    Yes 
    No 
 
 
5 (11.1%) 
40 (88.9%) 
 
 
5 (11.1%) 
40 (88.9%) 
 
 
1.00 
 
 
0.27-3.73 
 
 
1.00 
Hematocrit 
    Decreased 
    Not decreased 
 
12 (26.7%) 
33 (73.3%) 
 
16 (37.2%) 
27 (62.8%) 
 
0.59 
 
0.25-1.50 
 
0.23 
Leukocyte count 
    Increased 
    Not increased 
 
22 (50.0%) 
22 (50.0%) 
 
23 (54.8%) 
19 (45.2%) 
 
0.83 
 
0.35-1.93 
 
0.66 
Glucose   1.00 0.99-1.00 0.95 
Fructosamine   1.00 0.99-1.00 0.70 
Cholesterol 
    Increased 
    Not increased 
 
15 (34.1%) 
29 (65.9%) 
 
24 (54.5%) 
20 (45.4%) 
 
0.43 
 
0.18-1.02 
 
0.05 
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Total protein 
    Increased 
    Not increased 
 
10 (22.7%) 
34 (77.3%) 
 
10 (22.2%) 
35 (77.8%) 
 
1.03 
 
0.38-2.79 
 
0.95 
Albumin 
    Decreased 
    Not decreased 
 
6 (13.6%) 
38 (86.4%) 
 
8 (17.8%) 
37 (82.2%) 
 
0.73 
 
0.23-2.31 
 
0.59 
Creatinine 
    Increased 
    Not increased 
 
7 (15.9%) 
37 (84.1%) 
 
11 (25.0%) 
33 (75.0%) 
 
0.57 
 
0.20-1.63 
 
0.29 
Urea 
    Increased 
    Not increased 
 
12 (27.3%) 
32 (72.3%) 
 
21 (46.7%) 
24 (53.3%) 
 
0.43 
 
0.18-1.04 
 
0.06 
Potassium 
    Increased 
    Not increased 
 
4 (9.5%) 
38 (90.5%) 
 
8 (17.8%) 
37 (82.2%) 
 
0.49 
 
0.14-1.76 
 
0.27 
Potassium 
    Decreased 
    Not decreased 
 
7 (16.7%) 
35 (83.3%) 
 
11 (24.4%) 
34 (75.6%) 
 
0.62 
 
0.21-1.78 
 
0.37 
Bilirubin 
    Increased 
    Not increased 
 
14 (37.8%) 
23 (62.2%) 
 
20 (57.2%) 
15 (42.8%) 
 
0.46 
 
0.18-1.17 
 
0.10 
Lipase 
    Increased 
    Not increased 
 
26 (59.1%) 
18 (40.9%) 
 
28 (65.1%) 
15 (34.9%) 
 
0.77 
 
0.33-1.85 
 
0.56 
Ketoacidosis 
    Yes 
    No 
 
13 (28.9%) 
32 (71.1%) 
 
17 (37.8%) 
28 (62.2%) 
 
0.67 
 
0.28-1.62 
 
0.37 
Concurrent disease 
    Yes 
    No 
 
20 (44.4%) 
25 (55.6%) 
 
24 (53.3%) 
21 (46.7%) 
 
0.70 
 
0.31-1.61 
 
0.40 
 23 
Type of insulin 
    Insulin glargine 
    Porcine insulin zinc suspension 
 
21 (46.7%) 
23 (53.3%) 
 
8 (30.8%) 
18 (69.2%) 
 
2.05 
 
0.74-5.71 
 
0.16 
(*) Age, body weight, glucose and fructosamine do not have frequencies listed because 402 
analyzed as continuous variables. 403 
OR, odds ratio; CI, confidence interval. 404 
405 
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Table 2. Multivariate analysis of predictors of diabetic remission. 405 
Chance of diabetic remission 
Variable 
OR CI95% p-value 
Age 1.23 1.04-1.46 0.01 
Hematocrit 
    Decreased 
    Not decreased 
0.48 0.14-1.69 0.26 
Cholesterol 
    Increased 
    Not increased 
0.36 0.11-0.87 0.04 
Urea 
    Increased 
    Not increased 
0.59 0.18-2.00 0.40 
Bilirubin 
    Increased 
    Not increased 
0.49 0.16-1.47 0.20 
OR, odds ratio; CI, confidence interval. 406 
407 
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Table 3. Univariate analysis of factors associated with duration of diabetic remission. 407 
The number of cats is provided in parentheses for each variable. 408 
Duration of diabetic remission 
Variable*,§ 
Median (days) HR CI95% p-value 
Age  0.99 0.85-1.16 0.92 
Gender 
    Neutered male (32) 
    Spayed female (13) 
 
1240 
1380 
 
1.69 
 
0.54-4.87 
 
0.39 
Breed 
    Pure-bred (11) 
    Cross-bred (30) 
 
3370 
1240 
 
0.34 
 
0.10-1.12 
 
0.38 
Body weight  0.67 0.46-0.98 <0.01 
Hematocrit 
    Decreased (12) 
    Not decreased (33) 
 
150 
1380 
 
3.03 
 
1.27-19.8 
 
0.02 
Leukocyte count 
    Increased (22) 
    Not increased (22) 
 
1240 
1380 
 
2.17 
 
0.80-6.25 
 
0.27 
Glucose  1.01 1.00-1.02 <0.01 
Fructosamine  1.00 0.99-1.00 0.50 
Cholesterol 
    Increased (15) 
    Not increased (29) 
 
1020 
1380 
 
1.81 
 
0.68-6.67 
 
0.29 
Total protein 
    Increased (10) 
    Not increased (34) 
 
n.a. 
1240 
 
1.35 
 
0.34-5.88 
 
0.64 
Urea 
    Increased (12) 
    Not increased (32) 
 
1240 
3370 
 
1.20 
 
0.39-4.01 
 
0.72 
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Bilirubin 
    Increased (14) 
    Not increased (23) 
 
1240 
1020 
 
1.28 
 
0.41-4.34 
 
0.64 
Lipase 
    Increased (17) 
    Not increased (27) 
 
150 
1020 
 
4.17 
 
1.61-16.7 
 
0.02 
Ketoacidosis 
    Yes (13) 
    No (32) 
 
1240 
1020 
 
0.50 
 
0.17-1.39 
 
0.27 
Concurrent disease 
    Yes (20) 
    No (25) 
 
1380 
1240 
 
1.52 
 
0.57-4.35 
 
0.73 
Type of insulin 
    Insulin glargine (21) 
    Porcine insulin zinc suspension (23) 
 
n.a. 
1240 
 
0.88 
 
0.27-2.70 
 
0.79 
(*) Kaplan-Meier analysis is used for dichotomous variables; variables with less than 10 409 
cases in one category are not assessed (i.e., previous administration of corticosteroids 410 
and progestagens, serum albumin, creatinine and potassium). 411 
(§) Univariate Cox proportional hazard model analysis is used for continuous variables, 412 
including age, body weight, glucose and fructosamine. 413 
HR, hazard ratio; CI, confidence interval; n.a., not available. 414 
415 
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Table 4. Multivariate analysis of factors associated with duration of diabetic remission. 415 
Duration of diabetic remission 
Variable 
HR CI95% p-value 
Body weight 0.65 0.42-0.99 0.04 
Glucose 1.01 1.00-1.02 0.02 
Hematocrit 
    Decreased 
    Not decreased 
2.94 0.86-10.1 0.08 
Lipase 
    Increased 
    Not increased 
1.61 0.42-6.25 0.49 
HR, hazard ratio; CI, confidence interval. 416 
417 
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Figure legends 417 
Fig. 1. Diabetic cats achieving clinical remission. Cumulative percentage of cats that did 418 
not require insulin to maintain normoglycemia over time. 419 
 420 
Fig. 2. Percentage of diabetic cats achieving clinical remission at different age of 421 
diagnosis. 422 
 423 
Fig. 3. Duration of clinical remission and body weight at diagnosis in diabetic cats 424 
followed-up until death. Mean and standard deviation are reported. 425 
 426 
Fig. 4. Duration of clinical remission and glucose concentrations at diagnosis in diabetic 427 
cats followed-up until death. Mean and standard deviation are reported. 428 
